ODYSSEY Outcomes reports that post-ACS patients with starting LDL-C levels greater than 100 mg/dL benefited most, but you have noted the importance of assessing “aggregate risk” when identifying triggers for PCSK9-based therapy. Can you discuss this?

ODYSSEY Outcomes reports that post-ACS patients with starting LDL-C levels greater than 100 mg/dL benefited most, but you have noted the importance of assessing “aggregate risk” when identifying triggers for PCSK9-based therapy. Can you discuss this?

CLICK HERE FOR CME CREDIT

ODYSSEY Outcomes reports that post-ACS patients with starting LDL-C levels greater than 100 mg/dL benefited most, but you have noted the importance of assessing “aggregate risk” when identifying triggers for PCSK9-based therapy. Can you discuss this?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Christian Ruff, MD

Christian Ruff, MD

Christian Ruff, MD Principal Investigator, ENGAGE-AF Trial TIMI Group Director, General Cardiology Brigham and Women’s Hospital Assistant Professor of Medicine Harvard Medical School Boston, MA